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ABSTRACT 
Purpose: Adult stem cells are among the new methods of approaching the treatment of myocardial tissue damage. The purpose 
of this review is to clarify misconceptions about stem cell therapy efficacy in clinical trials and provide a thorough understanding 
of adult stem cells as a future treatment for patients with myocardial infarction. Methods: A comprehensive review of literature 
was performed analyzing and comparing 12 clinical trials involving the treatment of patients with acute and chronic myocardial 
infarction. Results: Stem cell treatments carry an excellent safety profile with the ease of one-time dosing, and have shown 
dramatic functional improvements while reducing the recurrence of myocardial infarction and enhancing quality of life. Important 
changes with adult stem cell treatments include 1) formation of new cardiomyocytes, 2) sufficient and sustained improvements in 
cardiac output, 3) increased myocardial contractility, 4) decreased infarct zone diameter, 5) increased left ventricular function, 6) 
increased exercise ability, and 7) increased coronary perfusion secondary to neovascularization. Conclusion: At this time, 
based on the current clinical evidence, adult stem cell therapy is in a position to be considered as an optional treatment for 
patients with acute or chronic myocardial infarction. Adult stem cell therapy is still in experimental stages of development and the 
continued clinical involvement will provide more evidence to the therapeutic effects of the treatment. 
 
INTRODUCTION 
Acute and chronic myocardial infarctions (MI) represent significant causes of morbidity and mortality throughout the world today. 
According to the CDC National Vital Statistics Report released in January 2008, heart disease remains the leading cause of 
death for adults in the United States.1 A variety of factors are recognized that may contribute to an increased risk of myocardial 
ischemia and infarction, including poor diet, smoking, environmental causes, genetic predisposition, coronary artery disease, 
diabetes or trauma. Considering the difficulty in controlling all predisposing factors, treatment for post-injury is particularly 
important. 
 
During myocardial ischemia, deprivation of oxygen to the tissue is detrimental to cardiac function. The cardiomyocytes that are 
unaffected by the injury are required to compensate for the loss in function, thus leading to ventricular dilation and wall thinning. 
This causes an increased stress on the ventricle which ultimately leads to hypertrophy of the cardiomyocytes. The most 
problematic effect of ventricular dilation is heart failure, resulting in a decreased cardiac output and function, and increasing the 
morbidity and mortality among these patients.2,3 Moreover, because of the limited regenerating capability of myocardial tissue, 
there is a reduction in the chance that full recovery will be a practical goal after MI.  
 
Currently, there are various medical interventions available such as medications, catheterization, and stent placement that may 
facilitate a return in cardiac function after myocardial damage, but there is often a limited amount of improvement. The initial goal 
in treatment of acute MI is reperfusion with percutaneous intravenous intervention (PCI) and ablation of clots with thrombolytic 
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therapy.3 Treatment of MI is currently focused on reducing the extent of ischemic damage and increasing the non-infarcted tissue 
function to replace damaged tissue. Since myocardial repair is limited with the use of current treatment techniques, new options 
are needed for more effective cardiac revival, whether as a novel treatment or a supplement to current therapy.  
 
Research is continuing throughout the world on the use of adult stem cells to treat many diseases and injuries. New studies have 
provided a variety of ways to treat both acute and chronic MI utilizing stem cells that can be found in various regions throughout 
the adult human body. Even though there has been extensive research done, standard treatments with stem cells have not been 
accepted because of many factors, including lack of understanding and large population testing. 
 
Stem cells, by nature, are the primitive form of all specialized cells in the body. Through successive divisions, the cell is capable 
of producing any specialized cell in the body, including cardiac muscle. It is a misconception that all stem cells are derived from a 
fetus or embryo. Though a fetus can provide cells in their primitive form, stem cells may also be obtained from various parts of 
the adult body; they simply have less potential to differentiate without assistance. The major sources of adult stem cells used for 
treatment of MI include bone marrow, healthy cardiac tissue, circulating blood, and skeletal muscle tissue.4-7 Cells can be 
collected in their undifferentiated state from these areas, cultured in media with growth factors and other chemicals, and replaced 
into the body to treat injury. Embryonic, umbilical and, fetal, are all potential sources of stem cells, however these sources are 
unrelated to the patient they are intended to treat; thus, embryonic, umbilical and fetal stem cells carry risks of rejection in the 
treated individual. In the case of adult stem cells, they can be obtained directly from the patient being treated, thus eliminating 
the potential risk for rejection. Research has shown that adult stem cells are effective in the treatment of myocardial injury by 
regenerating cardiac muscle tissue as well as inducing the formation of new blood vessels in the region of infarction.5 
Progressing from basic tissue research to animal trials, along with human studies outside the United States, the potential for the 
use of stem cells as a treatment for MI is promising.  
 
The purpose of this review is to clarify misconceptions about stem cell therapy efficacy in clinical trials and provide a thorough 
understanding of stem cells as a future treatment for patients with MI. Compiled data from recent clinical studies show that adult 
stem cells are at a stage in which they can be used in combination with current standard of treatment to provide an optimal 
recovery of cardiac function in acute or chronic MI patients. As a result of the different studies and experiments, it has been 
determined that there is very little risk and few side effects for adult stem cell use in the treatment of acute and chronic MI. In 
contrast, many current treatments carry a large assortment of side effects and the efficacy varies between patients. Some 
current interventions hold the potential to be more life threatening to the patient than the infarct itself. The use of adult stem cells 
has shown to be a beneficial way to treat patients who experience myocardial infarction, and consideration should be given to 
the adoption of standard treatment to reverse the detrimental outcomes from ischemic damage to the myocardium. 
 
METHODS OF RESEARCH 
As a review of the literature, this study did not involve live subjects or interviews. Inclusion criteria for the present study include 
articles published after January 2000 in English or an English translation from a wide variety of journals, with subject heading 
acute and/or chronic myocardial infarction and adult stem cell treatment and/or transplantation. Search methods included a 
variety of resources provided by Nova Southeastern University in the form of original printed journals or online accessible 
journals. Though human trials were the focus of research, animal trails were also reviewed and considered a vital portion of this 
review. Articles were not included in data presentation if it was not an original study, included treatment of heart failure not 
secondary to MI, or if the study exclusively involved granulocyte colony-stimulating factor in the trial. Those studies that 
discussed embryonic stem cells were completely omitted from this review. There were 12 clinical studies analyzed for the 
presentation of clinical evidence in adult stem cell therapy. 
 
CURRENT STANDARDS OF CARE  
According to an expert consensus document on the definition of myocardial infarction, the term should be used whenever there 
is an indication of necrosis.8 Table 1 summarizes the clinical criteria given by Thygesen and associates for the identification of 
acute and chronic MI. When a patient is diagnosed with acute MI, prompt treatment is the most important deciding factor in the 
extent of the cardiac injury. The current treatment for both acute and chronic MI involves similar methods attempting to limit 
ischemic damage and recover as much of the viable myocardium as possible.  
 
The current ACC/AHA Guidelines recommend, in the incidence of acute MI, that the best results for patient recovery are 
immediate PCI within 90 minutes of initiation of medical care. 9,10 In the acute care of MI, it is also recommended that a variety of 
medications are utilized to reduce the amount of ischemia by recovering coronary blood flow. The medications include nitrates, 
analgesics, beta-adrenergic blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors (ACE-I), antiplatelet/ 
anticoagulation therapy, and fibrinolytic therapy. After the acute treatment period, patients often remain on chronic therapy to 
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improve long-term prognosis with beta-blockers, calcium channel blockers, anti-lipid medications, ACE-I with or without the 
addition of a diuretic, and/or antiplatelet therapy.3,9,10 The current treatment for myocardial infarction is aimed at providing the 
best recovery for patients and preventing complications of heart failure, but new therapies are warranted to further improve 
patient outcomes. 
______________________________________________________________________________________________________ 
Table 1. Criteria for Acute and Chronic Myocardial Infarctiona 
Acute Myocardial Infarction Chronic/Prior Myocardial Infarction 
· Change in Cardiac Biomarkers with: 
o Symptomatic 
o ECG changes consistent with ischemia 
o Pathological Q waves on ECG 
o Imaging evidence of cardiac changes, 
thrombosis and/or injury 
· New pathological Q wave with/ without symptoms 
· Imaging evidence of myocardial changes and injury 
· Pathological findings of myocardial injury 
· Cardiac death  
· Infarction associated with PCI  
· Infarction associated with CABG  
· Infarction associated with stent thrombosis  
a Data adapted from Thygesen.8 ECG indicates electrocardiogram; PCI, percutaneous coronary intervention; CABG, coronary artery bypass 
graft. 
______________________________________________________________________________________________________ 
 
The goal of stem cell therapy is to provide an adjunct to the current post-MI treatment modality. It would not replace the current 
standards of care, but add an additional option to optimize the recovery of myocardial tissue after infarction. In clinical studies of 
adult stem cell therapy for MI, stem cell treatment patients did not receive any different post-treatment than the control patients, 
and all patients remained on the typical regimen of post-infarction medications after hospitalization.6,11 With the adjunct of adult 
stem cell therapy as a low-risk optional treatment, practitioners may find this new modality the ideal choice to salvage damaged 
myocardium.  
 
DIFFERENTIATION AND AVAILABILITY OF ADULT STEM CELLS 
Stem Cell Differentiation 
The mature heart is naturally unable to completely regenerate itself with new cardiac muscle cells, or cardiomyocytes. Cardiac 
muscles cells are highly specialized and are not easily replenished; instead, they are replaced by nonfunctional scar tissue. Scar 
tissue is incapable of performing the vital functions of cardiac muscle, and the heart often suffers decreases in compliance and 
cardiac output. Stem cells are the fundamental root of all cells and are capable of differentiating into any type of cell through 
successive divisions, whereas other cells are limited in their ability to become specialized tissue, such as cardiac or neural. Since 
the heart is comprised of very specialized cardiac muscle cells, stem cells are important in the regeneration of this tissue. The 
basic level of stem cell research is determining cell capability and growth requirements. In an effort to determine whether it is 
possible to generate cardiomyocytes from stem cells, several studies have been done with tissue and cell samples. These 
studies have established that cardiomyocytes can be created in the laboratory setting and hold the potential to be used in cell 
transplantation.12,13 
 
In an analysis of deceased human hearts that suffered from hypertension or coronary heart disease, it was determined that the 
heart contains cells in their primitive state, which hold the potential to differentiate into new myocytes. Stem cell markers used to 
identify proteins in the cells found new cell formation in the hypertrophied areas of the heart.14 This finding was important 
because cardiac cells were commonly thought to be irreplaceable and the typical increases in heart mass were a result of 
hypertrophy of only existing cells. However, it was found that the heart not only replaces some of the cardiomyocytes, but that it 
possesses a reserve of stem cells.14  
 
In a similar study, male heart transplant recipients that were given female hearts were biopsied and found to have new 
cardiomyocytes of non-cardiac origin within the foreign heart.15 Genetic changes were observed by detecting the male Y 
chromosome within the cardiomyocyte nuclei. As a control, non-transplanted female myocardial tissue biopsies were analyzed 
and lacked the presence of Y chromosomes. In addition, a male non-transplanted heart was analyzed and found to carry the Y 
chromosome in approximately 66.47% of the cardiomyocytes. When examining the male recipient’s new heart several months 
after transplant, the presence of Y-chromosomes (less than 0.2%) indicated that new cells were formed. It is important to 
consider that female hearts do not contain the Y chromosome, and since only 66% of the male heart contains Y chromosomes, it 
is probable that a greater amount of regeneration occurred than detected in the study. Unfortunately, the heart is not capable of 
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producing enough new cardiomyocytes to recover from the tissue loss from a typical MI. As a result, it was suggested that, 
“although the percentage of regenerated cardiomyocytes is rather low, the mechanism could be used to replace damaged 
myocardium by raising the numbers and by promoting the migration of the respective precursor cells into the damaged 
myocardium.”15 
 
The most intriguing tissue experimentations involve the growth of beating cardiomyocytes in the laboratory. When cultured under 
specific conditions, bone marrow stem cells (BMSCs) can be differentiated into cardiac muscle cells that beat on their own after a 
two-week period, and synchronously in three weeks. It was also found that the cells formed into specific types of cardiac muscle 
cells (sinus node and ventricular) based on their electrical action potentials.12 In a study by Matsuura and associates, Sca-1+ cells 
(cardiac stem cells) were acquired from the hearts of wild mice and used to grow cardiomyocytes in the lab.13 They were able to 
culture the cells and develop cardiac cells that would beat in the media. The differentiated Sca-1+ cells were then tested for other 
cardiac properties by exposing them to various cardiac drugs, including Isoproterenol, which has the ability to increase heart 
rate. The addition of cardiac drugs established that the cultured cells had the rate properties of typical cardiomyocytes by 
increasing and decreasing the rate of beating.  
 
An important factor in basic stem cell research is determining if the stem cells utilized in therapy are actually incorporated into the 
heart. Stem cells have not only shown the ability to differentiate into new myocardial tissue, but that differentiation only occurs in 
the presence of ischemia or other chemical signals.16 The cell engraftment exclusively in damaged myocardium indicates that, in 
fact, it is the stem cell infusion that is causing myocardial remodeling in patients receiving the treatment. Since basic tissue 
studies have provided fundamental evidence that stem cells can be induced to differentiate into beating cardiomyocytes, this 
shows the potential for adult stem cells to be used in the treatment of cardiac tissue injury.  
 
Availability of Adult Stem Cells 
Red bone marrow is the most common, and possibly the most efficient, site for stem cell collection. Bone marrow is a major 
manufacturing center for cells and a storage facility for a variety of stem cells. The cells contained in the bone marrow vary in the 
degree of differentiation, but can be separated using centrifugation or other available methods of cell separation. To maximize 
results, the bone marrow stem cells (BMSCs) are aspirated from the large bones, most commonly the iliac crest, then mixed with 
heparin and filtered.4,17,18 Large quantities of the BMSCs can be collected or the cells may be grown from a small quantity in 
growth media, and can then be delivered to the patient for treatment.16,19,20 In some cases, specific types of BMSCs have been 
isolated and used for treatment of MI, such as mesenchymal stem cells (MSCs), which were found in collected bone marrow to 
successfully treat rat models with cardiac injury. The MSCs are a rare type of cell found in bone marrow, but are descendants of 
the original stem cell, making them more differentiated. When used to treat cardiac ischemia they have been found to be highly 
effective through their ability to become cardiomyocytes.4,17,21 
 
In addition to bone marrow, other less common sources of stem cells that have the potential to become cardiomyocytes include 
the heart tissue itself, circulating blood, and skeletal muscle. It has been found that the heart contains cells in the primitive state, 
which hold the potential to be used for treatment of cardiac injury.13 Since the heart contains the well-differentiated myocytes that 
do not have the ability to repair damaged tissue, the stem cells have to be isolated from the tissue collection. Cardiac stem cells 
isolated and cloned from the heart ventricles of rat subjects have shown to be effective in the treatment of myocardial ischemia in 
the rat model, therefore making the heart a viable source of stem cells for myocardial repair.5 Circulating progenitor cells (CPCs) 
are an additional cell type easily obtained though venous blood centrifugation. After collection of a sufficient amount of CPCs and 
injection into the region of damage, the treatment successfully increases cardiac perfusion and function.6 However, CPCs were 
shown to be less effective than BMSCs in treating patients with chronic MI.22 In several clinical trials, granulocyte colony-
stimulating factor (G-CSF) was used to mobilize the stem cells from the bone marrow into circulation. The target of G-CSF 
administration is to increase the CPC concentration in blood to allow for sufficient collection. In addition, G-CSF will theoretically 
influence an increase in the incidence of natural regeneration secondary to the larger cell population in circulation. In these 
studies that utilized G-CSF, the CPCs were found to be more effective at regenerating myocardium than when used alone, 
therefore making them a viable source of stem cells for MI treatment.23,24 In addition, skeletal myoblasts have also been identified 
as useful precursors to cardiac muscle tissue.7 Although skeletal myoblasts have not been tested in humans, these cells possess 
the ability to function as cardiac tissue when collected from the hind leg muscles of rats, cultured in growth medium and used to 
treat MI.  
 
Bone marrow stem cells, cardiac stem cells, blood-derived stem cells and skeletal myoblasts have all been identified as effective 
types of cells in treatment of cardiac injuries. However, further studies are warranted to establish which type of stem cell is most 
effective and ideal for treatment of MI. It is possible that combinations or larger amounts of the different stem cells could be used 
to more effectively treat MI. 
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ADMINISTRATION OF STEM CELLS 
During administration of adult stem cells to treat myocardial infarction, the goal is to deliver enough cells to optimize repair in a 
manner that creates the least amount of side effects. The objective of cell isolation is to collect a sufficient number of cells for 
delivery. After collection, the cells are immediately isolated and either suspended or allowed to cultivate overnight. Following 
cultivation and suspension of the cells, it is important that the cells are administered in a heparin solution to prevent 
thromboembolus formation. Stem cell therapy is currently studied in patients that have already received the PCI treatment with or 
without stent placement. The ideal period of time to deliver the cells after primary catheterization has not been fully identified, but 
clinical evidence indicates that waiting more than 4 days has more benefit than immediate treatment.25,26 In addition, the most 
successful method of delivering the cultivated stem cells has not been completely established, but can include transvascular 
cardiac catheterization, direct needle injection, and peripheral intravenous (IV) administration. 
 
The most commonly utilized method of stem cell delivery is the transvascular approach by over-the-wire balloon catheterization 
of the infarcted coronary artery and injection of the cells directly into the infarct region. Injection with this method optimizes the 
repair of the infarcted region because the cells are introduced directly to the targeted tissue.17 The majority of reported stem cell 
therapy complications, however, occur from balloon catheterization and include local dissection of the artery and local wound 
infection at the site of catheter insertion.22 All clinical studies reported in this review utilized balloon catheterization when the stem 
cells were administered to the study patients.  
 
In animal models, direct needle injection of the stem cells into the infarcted regions of the heart has been used.4,7 This direct 
injection is an effective method of delivery for stem cells; however, it may not be ideal for human patients because of the need for 
an open-chest procedure. The opportunity to utilize this method of delivery is during an open-heart surgical procedure, such as a 
bypass, where the heart is already visualized and the surgeon can inject the stem cells into the regions of infarction. None of the 
clinical studies analyzed in this review utilized this method of administration. Direct injection of stem cells during transplant is a 
theoretical technique currently only used in laboratory research. 
 
Peripheral IV administration of drugs is very common in the treatment of MI as well as other injuries. In administration of stem 
cells via peripheral IV, concerns arise over the capability of the cells to repair the regions of infarction. Since the cells are 
administered through a peripheral vein, there is uncertain whether the cells will travel and engraft in the damaged area of the 
heart. In a study performed on rat subjects, it was found that IV administration is effective in reducing the infarct size and 
regenerating the myocardial tissue compared to control subjects. In addition, the stem cells were found to have induced new 
blood vessel formation in the ischemic tissue, thus allowing for increased blood perfusion to the damaged region.27 Though 
neovascularization has occurred in studies with central transcatheterization, the use of IV therapy could be more effective 
considering the cells have the advantage of reaching the tissue and vessels surrounding the infarct region. When using direct 
infusion, the cells primarily reach the area they are injected into, whereas IV administration is not necessarily limited to the 
immediate infarcted region. It is possible that the stem cells will also repair areas of the heart damaged during any previous injury 
and not detected by imaging, therefore preventing any future problems in that region. Since IV administration is safer for use on 
humans than catheterization, clinical trials utilizing IV therapy with humans would be a critical step for the standardization of stem 
cell treatment.  
 
STEM CELL DETECTION 
During the course of patient treatment, a variety of testing methods have been used to determine the viability of the stem cells 
and improvement to the myocardium. Echocardiography and angiography are the most common tests done to determine the 
patient’s cardiac function and output. The common cardiac volumes calculated with an echocardiogram include the end-diastolic 
volume (EDV), end-systolic volume (ESV) and stroke volume. Left ventricular ejection fraction (LVEF) delineates the volumes 
determined by the echocardiogram. Since the LVEF is the percentage (fraction) of blood ejected from the left ventricle with each 
contraction, end-diastolic and stroke volumes are important. Though LEVF may vary depending on patient size, in a healthy 
individual a LVEF over 55% is ideal, whereas in many cases of acute myocardial injury, the ejection fraction can drop below 
50%. When the calculated ejection fraction falls under 25%, there is indication of significant heart failure and can represent 
critical damage to cardiac muscle.  
 
Aside from calculated cardiac improvement, other methods to detect stem cell transplantation include the use of primers, 
magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), and position emission tomography 
(PET). These methods vary in their sensitivity of stem cell detection but are regularly utilized. All are able to provide similar or 
more accurate readings of volumes and LVEF compared to angiography or echo, but they are too expensive to be used in 
standard assessment of cardiac improvement. The additional methods of imaging are most useful in clinical studies because 
they provide more sensitive information with visualization of the infarct region and the amount of improvement from therapy. In 
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an animal study reported by Liu and associates, primers were used on the transplanted stem cells to track their implantation into 
the heart. They were able to show that the stem cells differentiated into cardiomyocytes by tracking the primer in pathological 
analysis of the myocardium after treatment.16 In the TOPCARE AMI trial, echocardiography was used in initial calculations of 
cardiac improvement and MRI was used around 9 days and 4 months post-therapy to corroborate the original observations.6,28 
The ability of MRI studies to provide a 3-dimensional image proves the study more reliable than echo alone. Other clinical 
studies have employed multiple methods of imaging with MRI, and SPECT or PET scanning, which are all conclusive in 
determining that stem cells are effective in regenerating myocardium and offer similar data in the myocardial changes.23,29,30 
 
CLINICAL EVIDENCE 
Clinical trials involving treatment of patients with MI using adult stem cells were first published in 2002, after animal experiments 
showed strong evidence that the therapy was effective in repairing damaged myocardium. Important changes in LVEF, coronary 
perfusion, myocardial contractility, infarct size, and exercise ability are the most effective methods of indicating the efficacy of 
cardiac treatment. The analysis of 12 clinical trials has provided evidence of beneficial ventricular remodeling and myocardial 
recovery from ischemia, and furthermore, established that adult stem cells are a reasonable treatment for MI. 6,11,17,22-26,29-32 All 
studies thus far have utilized either BMSCs or CPCs in random controlled environments administered via over-the-wire balloon 
catheterization after initial PCI. Patients in the cell treatment groups received the same standard of care therapy as the control 
group in addition to the stem cell treatment. A majority of the studies consisted of a small study group of approximately 30 to 60 
patients divided between control and treatment groups. Two of the studies had patient groups greater than 100, but there has not 
been a clinical study with an enrollment larger than 200 patients.   
 
The treatment of MI with adult stem cells has clear clinical benefits for patients. Increased cardiac output is the most commonly 
reported advantage of stem cell therapy. As presented in Figure 1, it is evident that the change in ejection fraction in the stem 
cell groups is greater than that of the control groups. 
______________________________________________________________________________________________________ 
 
Figure 1. Average Change in Ejection Fraction of Clinical Trials 
______________________________________________________________________________________________________ 
 
 
Future Implementation of Adult Stem Cell Therapy in the Current Standards of Care for Myocardial Infarction                                    8 
 
 
© The Internet Journal of Allied Health Sciences and Practice, 2008 
 
In a few studies, the improvement is only slightly more than that of the control; however, there is always a greater increase in the 
cell therapy group. The compiled data in Table 2 indicates average changes in ejection fraction of 11 clinical studies. Change in 
LVEF in the cell treatment groups range from +5% to +18%, whereas the control groups had a range from -1.2% to only +7.9%. 
The average improvement in ejection fraction calculated in the cell therapy group compared to the control groups was +4.1 
(55%) with a range of +0.2 (3%) to +12 (88%), indicating significant increases in cardiac function. The cell infusion groups of 
acute MI trials had average decreases in left ventricular EDV and ESV after follow-up analyses, and the control groups had 
average increases in both EDV and ESV, as shown in Table 3. The average decrease in EDV and ESV correlates with a 
decrease in the size of the left ventricle, indicating the possible prevention of left ventricular dilation that often transpires post-MI. 
______________________________________________________________________________________________________ 
Table 2. Effects of Stem Cell Therapy in Acute and Chronic MI on Ejection Fractiona 
Clinical Study 
Reference 
Acute/ 
Chronic MI 
Patients LVEF Changeb (%) Treatment Effect on 
LVEF  
(% Improvement)c 
Cell group Control Cell Group Control 
ASTAMI 29 Acute n=50 n=50 +8.1 +7.9 +0.2 (3%) 
BOOST 32 Acute n=30 n=30 +5.9 +3.1 +2.8 (48%) 
Chen 17 Acute n=34 n=35 +18 +6 +12 (67%) 
IACT Study 30 Chronic n=18 n=19 +8 +1 +7 (88%) 
Janssens 11  Acute n=30 n=30 +3.4 +2.2 +1.2 (35%) 
MAGIC Cell 23 Mixed n=10 n=10 +10 +6.9 +3.1 (31%) 
REPAIR-AMI 25 Acute n=95 n=92 +5.5 +3 +2.5 (46%) 
Strauer 26 Acute n=10 n=10 +5 +4 +1 (33%) 
TOPCARE AMI 6 Acute n=19 n=10 +8.5 +2.5 +6 (71%) 
TOPCARE CHD 22 Chronic n=69 n=23 +2.5 -1.2 +3.7 (76%) 
Zhan 24 Acute n=35 n=23 +7.1 +1.6 +5.5 (78%) 
Averages    +7.5 +3.4 +4.1 (55%) 
a MI indicates myocardial infarction; LVEF, left ventricular ejection fraction. 
bValues are given as mean unless otherwise indicated. 
cTreatment effect calculated as the difference between cell group and control group. 
______________________________________________________________________________________________________ 
 
In clinical studies that investigated the effects of stem cell therapy on the region of infarction, there is evidence of significant 
decreases in infarct size and ventricular contractility. During an active MI, the immediate perimeter around the dead tissue is 
surrounded by a region of ischemia. Once there is reperfusion to the coronary artery, the ischemia can be resolved but the infarct 
zone remains. The infarct zone contains non-functional myocytes that are normally remodeled by scar tissues. With current 
standard treatment, the infarct zone has little to no recovery in function; however, adult stem cells have the ability to considerably 
reduce the extent of infarction. Table 4 provides compiled data on the effects of stem cell therapy of infarct size, providing 
evidence of changes up to 60%. The ICAT and TOPCARE-CHD studies were clinical trials of patients with chronic MI, where 
recovery using current therapy was near the maximum.22,30 Revival of the cardiac tissue in the infarct zone can be attributed to 
improvement in the contractile function of the left ventricle and enhances the functional activity of the heart.28 The remodeling of 
the tissue within the infarct region is imperative to the increased function of the heart, and it is physiologically improbable that the 
typical scar tissue is responsible for such a significant improvement. The ICAT study was also able to show a 15% increase in 
glucose uptake in the recovered infarct region, indicating a regeneration of myocardial tissues capable of normal function. The 
improvement of the myocardium in the infarct border zone has resulted in beneficial increases in wall motion and systolic 
function.32 Additional studies have also indicated comparable results of contractile recovery, demonstrating that adult stem cell 
therapy is effective in providing functional recovery of myocardium.25,26 
 
In a number of MI cases, the existing coronary vascular supply is compromised by plaque formations that lead to the arterial 
blockage. Since the existing vasculature is not sufficient to supply the myocardial tissue with the critically needed oxygen and 
nutrients, new blood vessel formation, or angiogenesis, would likely benefit the infarct regions after an MI. Stem cell 
transplantation has shown to induce angiogenesis at the site of injury. 
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Table 3. Comparison of Volume Changes in Acute MI Clinical Trialsa 
 
Clinical Study Reference Patients LV EDV (ml) LV ESV (ml) 
Baseline Follow-up Baseline Follow-up 
ASTAMI 29 
BMSC Infusion 
Control 
 
n=50 
n=50 
 
162.3±59 
148.0±46 
 
151.1±52 
146.0±50 
 
n/a 
n/a 
 
n/a 
n/a 
Chen 17 
BMSC Infusion 
Control 
 
n=34 
n=35 
 
169.0±21 
n/a 
 
131.0±19 
n/a 
 
76.0±18 
n/a 
 
58.0±13 
n/a 
MAGIC Cell 23 
CPC Infusion 
Control 
 
n=10 
n=10 
 
133.0±34 
124.2±33 
 
111.7±37 
134.6±50 
 
70.3±28 
61.8±35 
 
61.8±35.8 
67.9±44 
REPAIR-AMI 25 
BMSC Infusion 
Control 
 
n=95 
n=92 
 
128±38 
139±46 
 
141±43 
153±57 
 
67±26 
75±32 
 
67±30 
80±45 
TOPCARE AMI 6 
BMSC/CPC Infusion 
Control 
 
n=19 
n=10 
 
117.2±35 
102.0±23 
 
105.2±29 
123.0±50 
 
56.1±20 
50.4±17 
 
42.2±15 
58.2±32 
Zhan 24 
CPC Infusion 
Control 
 
n=35 
n=23 
 
134.2±36 
122.1±35 
 
119.2±30 
113.5±24 
 
63.8±24 
59.4±25 
 
52.6±20 
52.6±9 
Averages 
Cell infusion 
Control 
 
 
 
140.6 
127.0 
 
126.5 
134.0 
 
66.6 
61.6 
 
56.3 
64.6 
______________________________________________________________________________________________________ 
Animal research first discovered this increase in capillary density which allowed an increase in the number of stem cells that 
reached the damaged tissue, permitting a greater amount of regeneration. It was also suggested that the neovascularization 
allowed for a more effective delivery of the necessary nutrients and growth factors to allow for greater proliferation of the new 
cells.33 In clinical studies, there is evidence that the capillary and larger vessel density was greater in the infarct region of stem 
cell treated patients than in the control patients. It was also noted that the beneficial effects from the neovascularization and 
myocardial regeneration was maintained for 4 years in the stem cell patient groups.31 The increased perfusion is imperative to 
the functional recovery and can be attributed to improvements of cardiac performance at rest and during stress.23 The stimulation 
of angiogenesis is reassuring and indicated that stem cell therapy has a number of positive effects in treatment of MI. The vessel 
formation in initial treatment could be beneficial in future analysis of repeat treatments in stem-cell-treated patients since the 
revascularization provides greater opportunity for the cells to reach infarct regions.  
__________________________________________________________________________________________________________________ 
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Table 4. Change in Infarct Size for Stem Cell Therapy Trials in MIa 
Clinical Study Patients (n) Change in Extent of Infarction (%) 
Pre-Treatment Post-Treatment  Change- no. (%) 
IACT Study 30 
    BMSC Infusion 
    Control 
 
n=18 
n=18 
 
27 
27 
 
19 
26 
 
-6 (30%) 
-1 (4%) 
Strauer 26 
    BMSC Infusion 
    Control 
 
n=10 
n=10 
 
30 
25 
 
12 
20 
 
-18 (60%) 
-5 (20%) 
TOPCARE CHD 22 
    BMSC Infusion 
    CPC Infusion 
    Control 
 
n=35 
n=34 
n=23 
 
45 
52 
45 
 
42 
50 
45 
 
-3 (7%) 
-2 (4%) 
0 (0%) 
aValues are given as mean unless otherwise indicated. EF indicates ejection fraction; LV,  
Left ventricular; BMSC,  bone marrow stem cells; CPC, circulating progenitor cells. 
______________________________________________________________________________________________________ 
 
The recovery acquired from the utilization of adult stem cells has been observed to have sustained clinical benefit for up to 4 
years after therapy. Several studies have corroborating data indicating that the functional recovery is not temporary, but remains 
a long term advantage to patients with myocardial damage.23,28,31 The follow-up data on cell treatment patients demonstrates that 
the myocardial and functional recovery continuously increased through the entire treatment period, indicating that stem cells 
have a continuous influence on remodeling, even after only one regimen of stem cells.23 With functional benefit after a single 
dose, adult stem cells hold a greater long-term clinical benefit than current medical treatment alone.  
 
When chronic and acute MI clinical study data was compared, it was found that there is no significant difference in myocardial 
benefit. The TOPCARE CHD and ICAT studies focused on chronic MI patients and the MAGIC CELL study combined both 
chronic and acute.22,23,30 In evaluation of the LVEF data compiled in Table 2, there is no significant difference between the 
chronic MI studies and the remaining acute MI studies. However, the stem cell treatment effects showed improvements of 76%, 
88%, and 31% respectively, compared to the control patients. The control patients in the chronic MI studies did not have a 
significant functional recovery on standard therapies, and in the ICAT report, there was a negative average LVEF change.30 
Considering chronically infarcted myocardium typically reaches a peak in functional recovery on standard therapy, the chronic 
treatment is focused on maintenance. With stem cell treatment, the evidence demonstrates that functional recovery is attainable 
after the standard therapy has reached a peak in the remodeling process. Therefore, those patients that do not elect stem cell 
treatment in the acute setting will still gain functional recovery from treatment months to years post-MI.  
 
The majority of studies have focused on patients with only mild loss in cardiac function and a LVEF typically not less than 45%. 
In several studies, there has been substantial documented evidence that patients with a worse baseline cardiac function had a 
larger overall recovery with cell therapy and significantly greater recovery than the control patients.11,23,25 The areas of most 
severe infarction gained the most benefit from cell therapy. In other words, the patients with more room to recover encountered a 
wider range of improvement from the stem cell therapy. In response to findings of impairment-dependant recovery, it was 
reported that “when combined with optimal reperfusion therapy (stent implantation) and state-of-the-art medical treatment, 
intracoronary administration of [BMSC] enhances the recovery of global and regional left ventricular function after myocardial 
infarction.”25(p1220) In clinical research of adult stem cell treatment of MI, there are a few issues that still remain: 1) the lack of 
large population testing in one study group, 2) the lack of studies involving patients with moderate to severe cardiac impairment, 
3) the lack of consistency of stem cell collection, and 4) unknown optimal cell concentrations. However, these issues are 
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relatively trivial to future implementation of adult stem cell therapy, considering the known benefits attained though the data 
provided from the current clinical studies. 
 
SAFETY AND MONITORING OF STEM CELL THERAPY 
It is important during the implementation of adult stem cell therapy to establish a satisfying safety profile. Many of the adverse 
events encountered during clinical studies were related to the PCI and stent procedures prior to therapy and non-treatment 
related issues rather than the stem cell therapy. The safety profile of PCI has already been established, but during clinical trials 
the major complications included 1) local dissection, 2) ventricular fibrillation, 3) stent thrombosis, and 4) ventricular 
tachycardia.22,24,29 In studies that utilized G-CSF, there were increased complications as a result of the mobilization of cells into 
circulation, and patients were at increased risk for thrombosis and bone pain.24 In evaluation of stem cell efficacy and safety, 
follow-up visits were necessary and regular throughout the patient treatment periods. In future treatments, continuous follow-up 
visits will be necessary for patients to monitor cardiac function and potential side effects. 
 
The collection and infusion procedures of stem cells have demonstrated minimal side effects and have shown to be a safe and 
feasible treatment for MI. In the 12 clinical studies investigated, all indicate through the reported results that adult stem cell 
therapy is a safe method of treatment for MI patients. Several reports express a lack of serious adverse reactions to the 
treatment, specifically illustrating no inflammatory processes, malignant arrhythmias, ischemic damages from infusion, or 
deaths.6,23,26,30 Complications that have transpired include restenosis, reinfarction, and microbial contamination.29,32 Many 
complications that arose during the treatment period were no more prevalent in stem cell treated patients than in the control 
patients receiving standard therapy. The stem cell therapy has shown to actually reduce recurrence of MI, which is a typical 
chronic effect of ischemia and coronary stenosis.25 In addition, treatment has not shown any significant difference between male 
and female populations.6 This evidence gives strong support to the safety profile of stem cell administration.  
 
DISCUSSION 
Clinical studies have provided sufficient evidence that adult stem cells are a viable resource in the treatment of acute and chronic 
myocardial infarctions. Stem cells can be obtained from a variety of locations, but the most beneficial outcome is obtained from 
bone marrow stem cells with delivery via over-the-wire balloon catheterization. Important changes that have been documented 
after treatments with adult stem cells include 1) formation of new cardiomyocytes, 2) sufficient and sustained improvements in 
cardiac output, 3) increased myocardial contractility, 4) decreased infarct zone diameter, 5) increased left ventricular function, 6) 
increased exercise ability, and 7) increased coronary perfusion secondary to neovascularization. The improvement in cardiac 
function aids to reduce the detrimental effects of chronic MI and prevents further complications in the patient. The functional 
benefits of adult stem cells are attained after a single dose and carry greater long-term clinical benefits than the current standard 
medical treatment. In addition, stem cell therapy has shown to reduce the rate of recurrence of myocardial infarction. 
 
At this time, based on the current clinical evidence, adult stem cell therapy is in a position to be considered as an optional 
treatment for patients with acute or chronic MI. Although stem cell therapies are still considered experimental, the continued 
clinical involvement of adult stem cell therapy will provide more evidence to the therapeutic effects of the treatment. At the 
moment, consideration needs to be given to those patients with severe cardiac functional deficits where current medical 
treatments are at a maximal effect. This is further supported by the evidence that stem cell therapy has more favorable effect on 
those patients with greater functional deficits. Patients with chronically sustained low cardiac output and ejection fractions less 
than 25% are at higher risk for further myocardial as well as systemic complications and need new additional treatments to 
increase cardiac survival. The benefits of stem cell therapy in such patients outweigh the minimal risks associated with the 
treatment. Patients with relative decreases in cardiac output and ejection fractions between 25% and 55% will still benefit from 
stem cell administration, and treatment options need to be made available to these patients. The prospect for adult stem cell 
therapy is promising for the future management myocardial tissue damage. With an excellent safety profile and the ease of one-
time dosing, adult stem cell therapy has shown dramatic functional improvements and reduces the recurrence of MI while 
enhancing quality of life for myocardial infarction patients. 
______________________________________________________________________________________________________ 
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